NCT00444093 2023-05-11
Loop
Philipps University Marburg
Phase 3 Terminated
Clinical Trials
9 trialsNCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT02080078 2019-05-03
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
AHS Cancer Control Alberta
Phase 1 Terminated
NCT02018653 2018-07-26
CASAD for Severe Diarrhea in the Emergency Department
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00040391 2016-12-01
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Celgene Corporation
Phase 2 Terminated
NCT01886287 2015-01-12
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01469338 2014-11-24
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Phase 2 Terminated
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated
NCT00036517 2005-06-24
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
PhytoCeutica
Phase 1/2 Terminated